邁博藥業-B(02181.HK)年度營業收入增加196.3%至2.58億元
格隆匯3月26日丨邁博藥業-B(02181.HK)公告,集團的營業收入由上年度的人民幣87.2百萬元增加196.3%至截至2024年12月31日止年度的人民幣258.2百萬元,主要是因爲報告期內集團CMAB009藥品新上市和CMAB007、CMAB008藥品銷售穩固增長以及獨家推廣許可權收入及CMAB806的合同研發生產協議收入增長。
公司擁有人應佔年內虧損及全面開支總額由上年度的人民 幣209.4百萬元減少38.9%至截至2024年12月31日止年度的人 民 幣127.9百萬元,主要是由於毛利增加及研發開支減少所致。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.